Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy.

Pharmacogenetics and genomics - 1 Oct 2016

Lewis Benjamin C, Korprasertthaworn Porntipa, Miners John O

Abstract excerpt

OBJECTIVES: To extend our understanding of how interindividual variability mediates the efficacy of cancer treatment. MATERIALS AND METHODS: The kinetics of dacarbazine (DTIC) N-demethylation by the most frequent polymorphic variants of CYP1A1 (T461N, I462V) and CYP1A2 (F186L, D348N, I386F, R431W, R456H) were characterized, along with kinetic parameters for the O-deethylation of the prototypic CYP1A substrate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Catalysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP1A1

Share to Cytochrome P-450 CYP1A2

Share to Dacarbazine

Share to Oxazines

Share to Prodrugs

Share to Substrate Specificity

Source

Identifiers

PMID: 27428168
DOI: 10.1097/FPC.0000000000000236

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy.PMID 27428168Read ↗

Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer TherapySemantic proximity Read ↗

From Genotype to Phenotype: Content and Activities of Cytochromes P450 2A6 in Human Liver In Vitro and Predicted In Vivo.Semantic proximity Read ↗

Contributing factors on metabolic mechanism-based CYP3A4-activated/deactivated anticancer drugs: implications for individualizing chemotherapySemantic proximity Read ↗

Generation, validation, and application of a P450 homology model.Semantic proximity Read ↗

Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity.Semantic proximity Read ↗

Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.Semantic proximity Read ↗

Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.Semantic proximity Read ↗

Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.Semantic proximity Read ↗

Personalized Dosing of Dichloroacetate Using GSTZ1 Clinical Genotyping Assay.Semantic proximity Read ↗

Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.Semantic proximity Read ↗

Inter-individual Variability in Activity of the Major Drug Metabolizing Enzymes in Liver Homogenates of 20 Individuals.Semantic proximity Read ↗

Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.